Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Change in Account Payables (2019 - 2025)

C4 Therapeutics (CCCC) has 7 years of Change in Account Payables data on record, last reported at -$472000.0 in Q4 2025.

  • For Q4 2025, Change in Account Payables fell 168.18% year-over-year to -$472000.0; the TTM value through Dec 2025 reached -$468000.0, down 293.28%, while the annual FY2025 figure was -$468000.0, 293.28% down from the prior year.
  • Change in Account Payables reached -$472000.0 in Q4 2025 per CCCC's latest filing, up from -$885000.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $1.5 million in Q2 2025 and bottomed at -$2.0 million in Q1 2021.
  • Average Change in Account Payables over 5 years is -$241300.0, with a median of -$324000.0 recorded in 2024.
  • The widest YoY moves for Change in Account Payables: up 314.55% in 2025, down 454.4% in 2025.
  • A 5-year view of Change in Account Payables shows it stood at $760000.0 in 2021, then crashed by 241.58% to -$1.1 million in 2022, then surged by 115.71% to $169000.0 in 2023, then crashed by 204.14% to -$176000.0 in 2024, then plummeted by 168.18% to -$472000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Account Payables were -$472000.0 in Q4 2025, -$885000.0 in Q3 2025, and $1.5 million in Q2 2025.